Pfizer strives to become the leading biotherapeutics company by building on internal expertise and fostering strategic partnerships to access the best technologies with patent protection and technical capabilities that provide a competitive advantage.
WRD is interested in establishing alliances to develop and access:
-
Transformational technologies to design, construct, and optimize biotherapeutics
- nformed protein design optimizes molecular properties resulting in superior efficacy, pharmacokinetics, pharmacodynamics, safety, manufacturability and differentions
-
Antibody drug conjugate technologies
- Novel ADC platforms, novel payloads, linkers, conjugation sites
-
Bioconjugation technologies
- Novel approaches that enhance antibody function or improve site-specific bioconjugation
- Combinatorial biologics such as bi-specific and multi-functional platforms with promising biophysical and manufacturing properties
-
Structure-based and computational design of therapeutics
- Novel technologies to rationally design antibody, protein and peptide therapeutics that display superior pharmaceutical properties (including selectivity, half-life extension, stability, formulatability)
- Technologies that enhance multi-transmembrane protein target expression/presentation for antibody generation and screening
- Technologies and patient sample access for antibody discovery from human antibody responses
- Targeted delivery technologies that address/ overcome cell membrane penetration, cross blood brain barrier
- Technologies that can significantly enhance general protein expression, purification, stability for discovery
- Integrated service providers to support early discovery activities for development of therapeutics
- Broadly applicable platforms to enhance speed/ quality of antibody generation
- Novel biologics, combination therapies, and "biobetters" that fit Pfizer strategies
Not actively seeking partnering opportunities in:
- PEGylation for bioconjugation
- Protein scaffold platforms with challenging stability attributes and/or difficult manufacturability